Ahmed A. Hassan

TL;DR: NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked.

TL;DR: An integrative in silico approach based on a primary target, NADPH oxidase type 4, to identify a mechanistically related cotarget, NO synthase, for network pharmacology, validating both in vivo and in vitro that both NOX4 and NOS inhibition is highly synergistic, leading to a significant reduction of infarct volume, direct neuroprotection, and blood–brain-barrier stabilization.

TL;DR: It is concluded that NOX5-induced uncoupling of endothelial NOS is a causal mechanism and theragnostic target of an age-related hypertension endotype.

TL;DR: This paper describes a two-fold approach of simultaneously applying the FAIR principles to scientific workflows as well as the involved data, and proposes a semantic model to address these specific requirements.

TL;DR: An inclusive and overarching approach to apply the FAIR principles to workflows and protocols and demonstrate its benefits is described and evaluated on a case study that consists of making the PREDICT workflow, a highly cited drug repurposing workflow, open and FAIR.